Poland· PL-100283673
Jakavi
A ruxolitinib product containing ruxolitinibum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ruxolitinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EJ01 (ruxolitinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Ruxolitinib · ATC L01EJ01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ruxolitinib costs, country by country.
Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ruxolitinib · price per daily dose (30 mg)
USD · FX 28 Sept 2026
- CH Switzerland$223.34
The record
At a glance
URPL (Poland)- Active substance
- Ruxolitinibum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- L01EJ01
- ATC class
- Ruxolitinib
- Defined daily dose
- 30 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991053741
- gtin05909991053758
- gtin05909991000899
- gtin05909991053765
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
350 interactions on record for ruxolitinib.
Graded by severity as the source publishes them — 92 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ruxolitinib · interactions on record
350 records
- 92 severe
- 199 moderate
- 59 minor
Most severe, free to view
- LonafarnibA16AX20severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- DanaparoidB01AB09severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ruxolitinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJAKAVINovartis Europharm Limited, Dublin
- NetherlandsJakavi 5 mg, tabletNovartis Europharm Limited
- SwedenJakavi 5 mg TablettNovartis Europharm Limited
- FinlandJakaviOrifarm Oy
- SwitzerlandJakavi
- IcelandJakaviNovartis Europharm Limited*
- SpainJAKAVI 5 MG COMPRIMIDOSNovartis Europharm Limited
- NorwayJakaviNovartis Europharm Limited (1)
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Polink, Ruxib
- Bulgaria · Руджави, Руксолитиниб Сандоз
- Cyprus · Ruxolitinib Sandoz
- Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
- Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
- Estonia · Ruxolitinib Msn
- Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
- Finland · Ruxolitinib Orion
- France · Ruxolitinib Biogaran, Ruxolitinib Olpha
- United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
- Greece · Jakulya
- Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
- Hungary · Ruxolitinib Sandoz
- Iceland · Jakavi, Jakulya
- Italy · Ruxolitinib Vivanta
- Liechtenstein · Jakavi, Opzelura
- Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
- Latvia · Ruxolitinib Msn
- Malta · Donlize, Ruxolitinib Medichem
- Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
- Norway · Jakavi, Opzelura
- Romania · Ruxolitinib Msn
- Sweden · Ruxolitinib Devatis, Ruxolitinib Orion
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec79b029-38ec-402a-a22a-5e80a18e0cc8 GET /v1/drugs/ec79b029-38ec-402a-a22a-5e80a18e0cc8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "5 mg",
"packaging": "05909991053741 ¦ Rpz ¦ EU/1/12/773/004 ¦ 33204\n14 tabl.\n05909991053758 ¦ Rpz ¦ EU/1/12/773/005 ¦ 33814\n56 tabl.\n05909991000899 ¦ Rpz ¦ Skasowane ¦ EU/1/12/773/001 ¦ 78561\n60 tabl.\n05909991053765 ¦ Rpz ¦ EU/1/12/773/006 ¦ 83525\n168 tabl.",
"substance": "Ruxolitinibum 5 mg",
"common_name": "Ruxolitinibum",
"pl_product_id": "100283673",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ruxolitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.